Changchun BCHT Biotechnology

Changchun BCHT Biotechnology FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Changchun BCHT Biotechnology (688276.SS) as of Nov 5, 2026 is 64.42 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -58.56 % — a change of -210.01% (higher).

FCF Conversion

64.42 %

YoY

-210.01%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Changchun BCHT Biotechnology is 2025 64.42 % . FCF Conversion Rate (FCF/EBITDA) of Changchun BCHT Biotechnology was 2024 -58.56 % . It decreases by -210.01% higher compared to the previous year.

The Changchun BCHT Biotechnology FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
69.22 CNY
Jan 1, 2019
47.24 CNY
Jan 1, 2020
-30.27 CNY
Jan 1, 2021
-202.25 CNY
Jan 1, 2022
-138.22 CNY
Jan 1, 2023
-43.00 CNY
Jan 1, 2024
-58.56 CNY
Jan 1, 2025
64.42 CNY
The Changchun BCHT Biotechnology FCF Conversion history
YEARFCF ConversionYoY
64.42 %-210.01%
-58.56 %+36.18%
-43.00 %-68.89%
-138.22 %-31.66%
-202.25 %+568.22%
-30.27 %-164.07%
47.24 %-31.76%
69.22 %-23.52%
90.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Changchun BCHT Biotechnology Stock analysis

What does Changchun BCHT Biotechnology do? Changchun BCHT Biotechnology Co. generates revenue through the research and development, production, and sale of human vaccines. The company operates from its headquarters in Changchun, Jilin, and leverages a workforce of 1,252 full-time employees to support its core business activities. Its primary market focus is the domestic market, where it distributes its approved vaccine products to customers seeking prevention and control solutions for infectious diseases. The firm's product portfolio includes three approved vaccines: the varicella vaccine, the rabies vaccine, and the freeze-dried nasal spray flu vaccine. These established products form the basis of its current commercial operations. Additionally, the company is expanding its pipeline with other vaccines under development, alongside a fully human monoclonal antibody also in development, to further address the needs of the infectious disease prevention sector. Changchun BCHT Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Changchun BCHT Biotechnology stock

FCF Conversion Rate (FCF/EBITDA) of Changchun BCHT Biotechnology is 64.42 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Changchun BCHT Biotechnology changed from -58.56 % to 64.42 %, representing a -210.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Changchun BCHT Biotechnology since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Changchun BCHT Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Changchun BCHT Biotechnology

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Changchun BCHT Biotechnology